FDA Approves Merck Tumor Treatment for DNA-Linked Cancers

In a move towards general cancer treatment, the FDA has approved Merck’s cancer drug for the treatment of any advanced tumor with microsatellite instability or DNA mismatch repair defects. Variants of these DNA indicators are present in genetically-linked cancers. The...

Low Cost Oncology Transition

Oncology Care: The Low Cost Transition Oncology Care:The Low-Cost Transition   In recent years, providers have added a renewed focus on the patient experience and overall care costs, in hopes to reduce the latter while improving the former. To successfully...